Selected Publications
Zhang L, Choi HJ, Estrada K, Leo PJ, Li J, Pei YF, et al. Multistage genome-wide association meta-analyses identified two new loci for bone mineral density. Hum Mol Genet. 2013; Epub 2013/11/20.
Wong IP, Nguyen AD, Khor EC, Enriquez RF, Eisman JA, Sainsbury A, et al. Neuropeptide Y is a critical modulator of leptin's regulation of cortical bone. J Bone Miner Res. 2013; 28:886-98.
van Geel TA, Eisman JA, Geusens PP, van den Bergh JP, Center JR, Dinant GJ. The utility of absolute risk prediction using FRAX and Garvan Fracture Risk Calculator in daily practice. Maturitas; 2013. Epub 2013/11/30.
Styrkarsdottir U, Thorleifsson G, Sulem P, Gudbjartsson DF, Sigurdsson A, Jonasdottir A, et al. Nonsense mutation in the LGR4 gene is associated with several human diseases and other traits. Nature. 2013; 497:517-20.
Nair P, Lee P, Reynolds C, Nguyen ND, Myburgh J, Eisman JA, et al. Significant perturbation of vitamin D-parathyroid-calcium axis and adverse clinical outcomes in critically ill patients. Intensive Care Med. 2013; 39:267-74.
Eisman JA, Bogoch ER, Dell R, Harrington JT, McKinney RE Jr, McLellan A, Mitchell PJ, Silverman S, Singleton R, Siris E; for the ASBMR Task Force on Secondary Fracture Prevention. Making the first fracture the last fracture: ASBMR task force report on secondary fracture prevention. J Bone Miner Res. 2012; 27:2039-46.
Center JR, Bliuc D, Nguyen ND, Nguyen TV, Eisman JA. Osteoporosis medication and reduced mortality risk in elderly women and men. J Clin Endocrinol Metab. 2011; 96:1006-14.
Bliuc D, Nguyen ND, Milch VE, Nguyen TV, Eisman JA, Center JR. Mortality risk associated with low trauma osteoporotic fracture and subsequent fracture in men and women. J Amer Med Assoc. 2009; 301:513-21.
Styrkarsdottir U, Halldorsson BV, Gretarsdottir S, Gudbjartsson DF, Walters GB, Ingvarsson T, Jonsdottir T, Saemundsdottir J, Center JR, Nguyen TV, Bagger Y, Gulcher JR, Eisman JA, Christiansen C, Sigurdsson G, Kong A, Thorsteinsdottir U, Stefansson K. Multiple genetic loci for bone mineral density and fractures, New Engl J Med. 2008; 358:2355-65.
Nguyen ND, Frost SA, Center JR, Eisman JA, Nguyen TV. Development of prognostic nomograms for individualizing 5-year and 10-year fracture risks. Osteoporos Int 2008; 19:1431-44.
Lundberg P, Allison SJ, Lee N, Baldock PA, Brouard N, Rost S, Enriquez R, Sainsbury A, Lamghari M, Simmons P, Eisman JA, Gardiner EM, Herzog H. Greater bone formation of Y2 knockout mice is associated with increased osteoprogenitor numbers and altered Y1-receptor expression. J Biol Chem 2007; 282:19082-91.
Gardiner EM, Baldock PA, Thomas GP, Sims NA, Henderson NK, Hollis B, White CP, Sunn KL, Morrison NA, Walsh WR, Eisman JA. Increased formation and decreased resorption of bone in mice with elevated vitamin D receptor in mature cells of the osteoblastic lineage. FASEB J. 2000; 14:1908-16.
Center JR, Nguyen TV, Schneider D, Sambrook PN, Eisman JA. Mortality after all major types of osteoporotic fracture in men and women: an observational study. The Lancet. 1999; 353:878-82.
Crofts LA, Hancock MS, Morrison NA, Eisman JA. Multiple promoters direct the tissue-specific expression of novel N-terminal variant human vitamin D receptor gene transcripts. Proc Natl Acad Sci USA. 1998; 95:10529-34.
Morrison NA, Qi JC, Tokita A, Kelly PJ, Crofts L, Nguyen TV, Sambrook PN, Eisman JA. Prediction of bone density from vitamin D receptor alleles. Nature. 1994; 367:284-7. Erratum in: Nature 1997 387:106.
Sambrook P, Birmingham J, Kelly P, Kempler S, Nguyen T, Pocock N, Eisman JA. Prevention of corticosteroid osteoporosis. A comparison of calcium, calcitriol and calcitonin. N Engl J Med. 1993; 328:1747-52.
Pocock NA, Eisman JA, Hopper JL, Yeates MG, Sambrook PN, Eberl S. Genetic determinants of bone mass in adults. A twin study. J Clin Invest. 1987; 80:706-10.
Morrison NA, Shine J, Fragonas JC, Verkest V, McMenemy ML, Eisman JA. 1,25-dihydroxyvitamin D responsive element and glucocorticoid repression in the osteocalcin gene. Science. 1989; 246:1158-61.
Frampton RJ, Omond SA, Eisman JA. Inhibition of human cancer cell growth by 1,25-dihydroxyvitamin D3 metabolites. Cancer Res. 1983; 43:4443-7.
Eisman JA, Suva LJ, Sher E, Pearce PJ, Funder JW, Martin TJ. Frequency of 1,25-dihydroxyvitamin D3 receptor in human breast cancer. Cancer Res. 1981; 41:5121-4.
Eisman JA, Martin TJ, MacIntyre I, Moseley JM. 1,25-dihydroxyvitamin-D-receptor in breast cancer cells. Lancet. 1979; 22-29:2(8156-8157):1335-6.
Eisman JA, Hamstra AJ, Kream BE, DeLuca HF. 1,25-Dihydroxyvitamin D in biological fluids: a simplified and sensitive assay. Science. 1976; 193:1021-3.
Eisman JA, Barkla DH, Tutton PJ. Suppression of in vivo growth of human cancer solid tumor xenografts by 1,25-dihydroxyvitamin D3. Cancer Res. 1987; 47:21-5.
Bilezikian JP, Canfield RE, Jacobs TP, Polay JS, D'Adamo AP, Eisman JA, DeLuca HF. Response of 1alpha,25-dihydroxyvitamin D3 to hypocalcemia in human subjects. N Engl J Med. 1978; 299:437-41.
More Garvan Publications
